These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12970355)

  • 1. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.
    Shindo K; Takaori-Kondo A; Kobayashi M; Abudu A; Fukunaga K; Uchiyama T
    J Biol Chem; 2003 Nov; 278(45):44412-6. PubMed ID: 12970355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
    J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G targets specific virus species.
    Kobayashi M; Takaori-Kondo A; Shindo K; Abudu A; Fukunaga K; Uchiyama T
    J Virol; 2004 Aug; 78(15):8238-44. PubMed ID: 15254195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
    Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between HIV-1 Gag and APOBEC3G.
    Cen S; Guo F; Niu M; Saadatmand J; Deflassieux J; Kleiman L
    J Biol Chem; 2004 Aug; 279(32):33177-84. PubMed ID: 15159405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
    Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
    J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Sheehy AM; Gaddis NC; Choi JD; Malim MH
    Nature; 2002 Aug; 418(6898):646-50. PubMed ID: 12167863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
    Ribeiro AC; Maia e Silva A; Santa-Marta M; Pombo A; Moniz-Pereira J; Goncalves J; Barahona I
    J Virol; 2005 Jan; 79(2):823-33. PubMed ID: 15613310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC-mediated editing of viral RNA.
    Bishop KN; Holmes RK; Sheehy AM; Malim MH
    Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC family proteins: novel antiviral innate immunity.
    Takaori-Kondo A
    Int J Hematol; 2006 Apr; 83(3):213-6. PubMed ID: 16720550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.